#United States #Los Angeles #Boston Scientific #Wisner Baum #Spinal Cord Stimulator

Leadership Appointments in Boston Scientific Spinal Cord Stimulator Litigation

In a significant development, two attorneys from Wisner Baum LLP have been appointed to crucial leadership positions in the multi-district litigation (MDL) concerning spinal cord stimulators produced by Boston Scientific. The litigation now resides in the U.S. District Court for the Central District of California, where serious allegations regarding device safety and manufacturer accountability are being examined.

Overview of the Appointments

Behram V. Parekh, a partner from Wisner Baum’s Los Angeles office, has been designated one of the three Co-Lead Counsel in the Boston Scientific spinal cord stimulator products liability litigation, MDL No. 3181. Complementing this leadership role, associate attorney Hannah Quicksell is set to contribute to the Litigation's Leadership Development Committee. This strategic shift marks an important change as the case progresses into an advanced stage of coordinated discovery.

The litigation witnesses patients accusing the spinal cord stimulators of failing to deliver expected pain relief and causing adverse effects, which include painful electrical shocks, increased pain, neurological complications, device malfunctions, and the necessity for surgical revisions or removals. Such legal claims raise essential questions regarding the practices of major device manufacturers.

Coordination of Federal Cases

The Judicial Panel on Multidistrict Litigation created MDL No. 3181 to ensure the efficient handling of federal legal matters regarding Boston Scientific's spinal cord stimulators. Judge Josephine L. Staton presides over these proceedings. As Co-Lead Counsel, Parekh's responsibilities will include overseeing pretrial activities, establishing litigation strategies, and orchestrating discovery efforts. His role is pivotal as lawyers seek to streamline the litigation process surrounding common inquiries, such as device safety and manufacturer practices.

The newly established leadership structure also encompasses a Plaintiffs' Executive Committee, a Plaintiffs' Steering Committee, and the Leadership Development Committee. Quicksell, along with her committee peers, will collaborate with senior leaders on various litigation projects, gaining invaluable leadership experience through mentorship opportunities.

Implications of the Litigation

This complex litigation will necessitate meticulous coordination and rigorous scientific investigation, as underscored by Parekh. He stated, "The purpose of leadership is to ensure that work is organized effectively and efficiently, while prioritizing the interests of the thousands of patients who have suffered injuries due to these devices."

Plaintiffs contend that Boston Scientific's spinal cord stimulators deviated from their initial FDA-approved designs without undergoing necessary clinical trials to ascertain the safety and efficacy of these modifications. Such allegations incorporate substantial concerns about the demands and obligations that manufacturers should meet regarding device design changes, regulatory compliance, and patient care.

In addition, the litigation against Boston Scientific is not isolated. Plaintiffs are also considering consolidating cases against other manufacturers like Abbott and Nevro, with an upcoming hearing scheduled for September 24 to evaluate these requests. Parekh notes that while each device may vary by manufacturer, many fundamental questions regarding the risks, modifications, and transparency to patients remain consistent.

Future Directions

With the leadership team now positioned, Wisner Baum's attorneys are set to forge a cohesive legal narrative and pinpoint the pivotal scientific, factual, and regulatory issues that will drive discovery and litigation processes. This may involve scrutinizing corporate documentation, analyzing adverse-event reports, and reviewing historical modifications and FDA dealings related to the devices.

The appointment of Parekh and Quicksell not only signifies an evolution from managing individual cases to influencing federal litigation but also reinforces Wisner Baum's commitment to upholding the rights of patients affected by these medical devices. "While we are in the nascent stages of these proceedings, the establishment of the MDL signifies a more structured approach to examine these claims thoroughly," Parekh remarked. "Our mission is to follow the evidence closely and ensure that victims of these devices receive fair representation in court."

About Wisner Baum

Wisner Baum is recognized nationally for advocating on behalf of individuals harmed by corporate neglect, hazardous products, environmental dangers, and systemic failures. Known for its trial expertise and rigorous investigative approach, the firm is at the forefront of significant litigation influencing industries and patient safety nationwide.
For more details, visit www.wisnerbaum.com.